$145.00 Out of stock Out of stock This product is intended for laboratory research use only
GLP-1 is primarily synthesized and secreted by specialized enteroendocrine cells called L-cells, which are located throughout the intestinal tract but are most concentrated in the distal small intestine (ileum) and colon
Investigating the same primary endpoint, TRANSCEND-T2D-2 (NCT06260722) will compare retatrutide to semaglutide in people with inadequately controlled T2D (treated with oral glucose-lowering treatments) over 26 months
Retatrutide also lowered fasting and postprandial glucose, reduced appetite, and improved lipid profiles, including reductions in low-density lipoprotein (LDL) cholesterol and triglycerides
Why the Combination Matters The three-receptor activity creates what researchers describe as a complementary pharmacological triangle: GLP-1 reduces intake, GIP enhances the metabolic benefits of incretin signaling, and glucagon increases energy output
doi: 10.3390/ijms17020190 74 RiederFZimmermannEMRemziFHSandbornWJ
